Lucentis, which recent research have shown performs no much better than Avastin at treating eyesight loss, costs about $2,000 per dosage. Avastin, which was developed by Genentech to treat colon and lung cancers originally, costs significantly less than $100 per dose. THE CHANGING TIMES article says that Genentech is trying to spin the program as an effort to motivate doctors to prescribe Lucentis for retinal vein occlusion, a condition that your US Food and Drug Administration authorized the medication for in June. However the ongoing company offers been investigated for Avastin-related chicanery before.‘Today's approval has an important additional treatment option for individuals with overactive bladder, a condition that affects around 33 million women and men in the United States.’ Botox's effectiveness and safety for this new indication were established in two clinical trials of 1 1,105 individuals with symptoms of overactive bladder. Patients were randomly designated to receive injections of 100 systems of Botox or placebo. Outcomes after 12 weeks showed that individuals treated with Botox experienced bladder control problems an average of 1.6 to 1 1.9 times less each day than individuals treated with placebo. Botox-treated patients had a need to urinate typically 1 also.0 to 1 1.7 times less per day and expelled an average of about 30 milliliters more urine than those treated with placebo.